HomeCompareCSASF vs MRK

CSASF vs MRK: Dividend Comparison 2026

CSASF yields 2.74% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSASF wins by $266.13M in total portfolio value
10 years
CSASF
CSASF
● Live price
2.74%
Share price
$23.61
Annual div
$0.65
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$266.19M
Annual income
$248,726,029.46
Full CSASF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — CSASF vs MRK

📍 CSASF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSASFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSASF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSASF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSASF
Annual income on $10K today (after 15% tax)
$232.60/yr
After 10yr DRIP, annual income (after tax)
$211,417,125.04/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, CSASF beats the other by $211,408,528.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSASF + MRK for your $10,000?

CSASF: 50%MRK: 50%
100% MRK50/50100% CSASF
Portfolio after 10yr
$133.12M
Annual income
$124,368,071.62/yr
Blended yield
93.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CSASF
No analyst data
Altman Z
1.4
Piotroski
4/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSASF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSASFMRK
Forward yield2.74%2.81%
Annual dividend / share$0.65$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$266.19M$57.7K
Annual income after 10y$248,726,029.46$10,113.78
Total dividends collected$264.87M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CSASF vs MRK ($10,000, DRIP)

YearCSASF PortfolioCSASF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,247$547.30$11,213$373.04+$34.00CSASF
2$13,185$1,150.59$12,667$512.06+$518.00CSASF
3$16,629$2,521.19$14,439$708.14+$2.2KCSASF
4$23,737$5,943.49$16,640$988.16+$7.1KCSASF
5$41,256$15,857.55$19,432$1,394.07+$21.8KCSASF
6$95,660$51,516.42$23,057$1,992.90+$72.6KCSASF
7$325,630$223,273.12$27,889$2,894.79+$297.7KCSASF
8$1,769,033$1,420,609.11$34,518$4,286.29+$1.73MCSASF
9$16,318,425$14,425,560.08$43,912$6,494.35+$16.27MCSASF
10$266,186,745$248,726,029.46$57,714$10,113.78+$266.13MCSASF

CSASF vs MRK: Complete Analysis 2026

CSASFStock

Credit Saison Co., Ltd. provides leasing, finance, real estate, entertainment, and payment services in Japan and internationally. The company offers credit cards, prepaid and debit cards, smartphone-based services, and loan collection services; and payment solutions and business support services for corporate activities, as well as marketing solutions. It also engages in the credit guarantee and finance related businesses; leasing of office equipment; servicing business; real estate business; real estate leasing activities; and digital payment and asset management services, as well as develops and manages amusement centers/arcades. The company was formerly known as Seibu Credit Co., Ltd. and changed its name to Credit Saison Co., Ltd. in October 1989. Credit Saison Co., Ltd. was incorporated in 1951 and is headquartered in Tokyo, Japan.

Full CSASF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CSASF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSASF vs SCHDCSASF vs JEPICSASF vs OCSASF vs KOCSASF vs MAINCSASF vs JNJCSASF vs ABBVCSASF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.